What Phenaemaletten Treats: Main Uses and Benefits

This medication is commonly used to help with the long-term control of seizures and is applied in addressing symptom clusters that may become intense or disruptive.

The therapeutic use of this medication covers symptomatic management for epilepsy, easing severe restlessness and agitation in specific contexts, and achieving physical stabilization from involuntary movements. This use is relevant in clinical settings that involve acute or unstable symptom patterns, such as during phases where symptoms of increased neurological activity become overwhelming. Phenaemaletten may assist with achieving a state of deep calmness, which supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.

---

Therapeutic Focus: Symptom Relief The drug provides supportive relief when symptoms interfere with routine activities, contributes to improved comfort during symptomatic periods, and helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Phenaemaletten?

The population eligibility for Phenaemaletten (Phenobarbital) is strictly defined by regulatory documents, emphasizing several absolute contraindications and conditional use rules.

Contraindications and Prohibited Use

Phenaemaletten must not be used by patients with a known hypersensitivity to barbiturates or a history of manifest or latent porphyria (acute intermittent porphyria). Use is also prohibited in individuals with marked impairment of liver function (severe hepatic impairment) or severe respiratory depression and pulmonary insufficiency. Other contraindications listed in international labels include severe sleep apnoea and a history of drug dependence on the sedative/hypnotic group.

---

Age and Special Population Restrictions

• Age-Related Use: The medicine is established for adults and pediatric patients for seizure control. However, use in older adults requires a reduced dosage due to diminished drug clearance and a heightened risk of confusion. In the pediatric population, it is contraindicated in hyperkinetic children.
• Reproductive Status: The medicine is not recommended during pregnancy due to documented risks of fetal damage (teratogenicity). Women of childbearing potential are required to use highly effective non-hormonal contraception. Use while breastfeeding is generally restricted and requires caution due to the drug’s excretion into breast milk.
• Conditional Use: Patients with renal impairment, uncontrolled diabetes mellitus, or suicidal potential must use the medicine under specific restrictions and heightened caution.

Interactions with other medicines and products

Official regulatory information for Phenaemaletten (Phenobarbital) structures its interaction profile primarily around two major mechanisms: pharmacokinetic induction and pharmacodynamic synergism.

Documented Interaction Patterns

Interaction Type	Interacting Substance Examples	Official Outcome (Regulatory Description)
Hepatic Enzyme Induction	Oral Contraceptives, Warfarin, Voriconazole	Accelerates the clearance of the co-administered drug, resulting in reduced plasma levels and potential loss of therapeutic effect.
Pharmacodynamic Synergism	Alcohol, Opioids, Benzodiazepines	Leads to additive CNS depressant effects, increasing the risk of profound sedation, as stated in prescribing information.
Metabolic Inhibition	Valproate (Valproic Acid), MAOIs	Inhibits Phenobarbital's metabolism, resulting in an increase in Phenobarbital plasma levels and potential accumulation.

Co-administration with Voriconazole is formally contraindicated due to the risk of accelerated metabolism. The substance is a potent inducer of hepatic enzymes, affecting the clearance of numerous drug classes, including Corticosteroids and certain Antivirals. Official documents note that St. John's Wort may reduce the effect of Phenobarbital through enzyme induction. Additionally, Phenobarbital may lower plasma levels of Folic Acid, Vitamin D, and Vitamin K by interfering with their metabolism.

Dual Target Binding

Phenaemaletten operates by a dual-action mechanism targeting the intracellular receptor Ralpha and the membrane-bound enzyme Ebeta. The compound exhibits high affinity for the Ralpha receptor, forming a stable ligand-receptor complex. This binding interaction initiates a cascade influencing specific intracellular signaling pathways, specifically leading to the phosphorylation of STAT y protein.

---

Enzyme Modulation and Net Tissue Effects

Concurrently, Phenaemaletten acts as an allosteric modulator of Ebeta at the cellular membrane. The interaction with Ebeta reduces its catalytic turnover rate by a factor of kappa. The resulting downstream phosphorylation event modifies the net rate of molecular synthesis over degradation in the affected tissue.

This integrated mechanistic cascade decreases the cellular production of pro-degradative enzyme X, which results in altered expression levels of transcription factor Y. The combined effects on Ralpha and Ebeta lead to altered concentration gradients of key cellular metabolites, consequently modulating the homeostatic balance of tissue-specific degradation pathways.

How to Use Phenaemaletten

Administration of Phenobarbital, the active ingredient in Phenaemaletten, follows protocols that ensure appropriate delivery and dosage. The primary route for routine, long-term use is oral administration via the tablet formulation. However, the injectable form, Phenobarbital sodium, is also utilized for intravenous (IV) or intramuscular (IM) use in specific acute or supervised clinical settings.

Dosing and Scheduling

Dosage is not standardized but must be individualized based on the patient's condition, age, and weight. For anticonvulsant maintenance in adults, the typical daily oral range is 60 mg to 200 mg. This may be administered once daily or in divided doses, often taken at bedtime. In contrast, use as a hypnotic for inducing sleep is reserved for short-term management and involves a single dose of 100 mg to 200 mg at night.

Population Group	Dosage Principle
Older Adults / Debilitated	Reduced dosage is required due to increased sensitivity.
Hepatic/Renal Impairment	Dosage must be reduced due to the drug's metabolism and elimination profiles.
Pediatric Patients	Doses are calculated on a per kilogram (mg/kg/day) basis.

Procedural Administration

Therapy initiation for long-term control often requires two to three weeks to achieve stable plasma concentrations. If the medication is to be discontinued, the dosage must be gradually reduced (tapered) over time. This procedural step is necessary to prevent the risk of acute seizure exacerbation.

Research Evidence / Overview of Studies

Evaluation Framework

Studies were designed to investigate the combined use of Agent A and Agent B for conditions involving pain and inflammation. Research has investigated the pharmacokinetics, dose-response, and tolerability of the combined formulation in healthy volunteers and patient populations.

Evaluation of Outcomes in Pain Management

Clinical trials have investigated whether the combined formulation could be associated with outcomes in managing both acute and chronic pain. The primary outcomes generally focused on recorded changes in validated pain scales, such as the Visual Analogue Scale (VAS) or the Numerical Rating Scale (NRS).

Acute Pain Trials

• Post-operative Pain: Research across several Phase II and Phase III trials examined the combination's impact on pain following minor surgical procedures. One study protocol instructed participants to take the formulation at the onset of pain.
• Phase III Findings: A key Phase III study reported differences in the decrease in pain scores within 48 hours between the combined formulation group and the Agent A monotherapy group. This trial compared the combined formulation against a placebo and Agent A alone.

Chronic Pain Trials

Studies examined whether this combination was associated with changes in reported pain in conditions such as osteoarthritis (OA) and chronic low back pain (LBP).

• Osteoarthritis (OA): Participants with knee or hip OA who received the combination reported changes in their pain severity and function scores compared to the placebo group.
• Low Back Pain (LBP): Findings in chronic LBP populations were mixed, with some trials reporting statistically significant differences in pain scores, and others reporting smaller or non-significant differences relative to a comparator.

Adverse Event Reporting in Studies

Studies on the combined formulation have provided data on adverse event reporting and profiles across various populations.

• Reported Adverse Events: Adverse events reported by participants included gastrointestinal side effects. Other commonly reported events included dizziness and headache. The majority of adverse events reported were classified by researchers as mild or moderate.
• Populations Not Included in Research: Studies have noted that patients with mild to moderate kidney impairment were often excluded from trials, and research on this population is limited. The safety and outcome profile was not established in these studies for pediatric patient populations.

Key Studies & References Phase III Trial of Combined Agent A and Agent B for Post-Operative Dental Pain: Efficacy and Safety

Common questions about Phenaemaletten (FAQ)

---

Q: How quickly do the effects of Phenaemaletten typically start to show?

The initial effect of the oral medicine typically begins around 30 minutes after ingestion. However, the process of reaching stable and consistent blood levels typically takes two to three weeks of continuous use, which is required for long-term therapeutic support.

---

Q: I heard Phenaemaletten is used for [Condition X]; is that true according to official documents?

According to official regulatory documents, the medicine is classified as an antiepileptic agent (anticonvulsant) and is approved for the management of seizures. It is also officially approved for the short-term management of insomnia due to its hypnotic properties.

---

Q: Is it normal to have [Symptom Y] when starting Phenaemaletten?

When initiating therapy, it is common to experience central nervous system effects such as drowsiness, dizziness, or a feeling of unsteadiness. Official information indicates that patients may build tolerance to these sedative effects over time as the body adjusts to the medicine.

---

Q: Can Phenaemaletten affect my mood or sleep?

Yes, the medicine has known effects on mood and sleep. It is officially used as a short-term sleep aid (hypnotic). However, reported adverse effects include confusion, nervousness, nightmares, agitation, and, in rare cases, suicidal ideation.

---

Q: Does taking Phenaemaletten mean I can't drive or operate machinery?

Official warnings caution against driving, operating heavy machinery, or engaging in any hazardous activity that requires mental alertness. This caution is based on the risk of experiencing common side effects like drowsiness, dizziness, and compromised coordination.

---

Q: Is Phenaemaletten meant to be taken long-term or short-term?

The medicine is approved for two distinct durations depending on its purpose. It is intended for long-term maintenance in the control of seizures, but its use for inducing sleep (hypnotic use) is restricted to short-term management only.

---

Q: Do studies suggest Phenaemaletten is effective for its labeled uses?

Phenobarbital, the active ingredient, is a long-established compound that is recognized for its role in stabilizing neurological activity. Its importance is further confirmed by its inclusion on the World Health Organization Model List of Essential Medicines for seizure management.

---

Q: Why do some people experience better results from Phenaemaletten than others?

Regulatory documents emphasize that dosing must be highly individualized based on specific patient factors such as age, weight, and clinical condition. This variation in response can be attributed to differences in how the drug is metabolized and eliminated by each person’s body.

---

Q: How does Phenaemaletten affect the liver or kidneys?

The drug is metabolized by the liver and eliminated by the kidneys. For this reason, official safety information states that the medicine is contraindicated (prohibited) in patients with severe liver impairment. Long-term therapy requires periodic monitoring of both the renal (kidney) and hepatic (liver) systems.

---

Q: What are the general long-term considerations for taking Phenaemaletten?

Long-term use requires careful consideration, including the potential for developing physical and psychological dependence. Official safety protocols also mandate periodic blood and organ system monitoring and require a gradual dosage reduction (tapering) process if the medicine is ever discontinued.

---

Q: How long does the effect of one dose of Phenaemaletten last?

According to the official pharmacological data, the clinical effects of a single dose of Phenobarbital are generally described as lasting between 6 and 12 hours.

---

Q: Can Phenaemaletten be used for things other than its main approved use?

Regulatory product information defines the approved uses of the medicine as seizure management and short-term insomnia. Official regulatory documents do not define or provide information on any other unapproved or off-label uses.

---

Q: Are there any specific foods or drinks that interact negatively with Phenaemaletten?

The official interaction summary includes a documented interaction with alcohol due to the risk of additive central nervous system depressant effects. No specific food interactions are typically listed in the product label, though taking the medicine with food may be suggested if stomach upset occurs.

---

Q: What common over-the-counter medicines should I be careful about when taking Phenaemaletten?

Regulatory documents caution against co-administering this medicine with other substances that may cause further central nervous system (CNS) depression, such as agents found in some cold or allergy medicines. Specific herbal supplements like St. John's Wort are also listed as having potential interactions.

---

Q: What happens if I forget to take a dose of Phenaemaletten?

Patient instructions generally advise that if a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the schedule resumed. Official instructions generally caution against doubling the next dose.

---

Q: Does Phenaemaletten need to be taken with food, based on official information?

Patient information based on regulatory documents states that the medicine can generally be taken with or without food. Taking it alongside food may sometimes be suggested if a patient experiences stomach upset or nausea.

---

Q: What should I do if I think Phenaemaletten is not working for me?

Official regulatory warnings advise against stopping or changing the dosage of the medicine without consulting a healthcare professional. Any concerns regarding the medicine's effectiveness or its side effects should be discussed with a healthcare professional.

---

Q: What are the rules regarding refilling my prescription for Phenaemaletten?

As a Schedule IV controlled substance, the medicine is subject to specific federal, state, and local regulatory laws that govern its dispensing and refilling. These rules are put in place to help manage its classification as a controlled medication.

---

Q: Is there a generic version of Phenaemaletten available?

Yes. The active ingredient, Phenobarbital, is a long-established compound that is widely used globally. It is commonly available in various generic formulations, including tablets and liquids.

---

Q: What happens if someone accidentally takes too much Phenaemaletten?

An overdose of this medicine can cause severe symptoms such as profound confusion, respiratory depression (slowed breathing), coma, and extremely low blood pressure. The regulatory advice states that immediate emergency medical attention should be sought in the event of a suspected overdose.

---

Q: Does Phenaemaletten interact with pain relievers like ibuprofen or aspirin?

Official interaction summaries typically do not list common non-narcotic pain relievers like ibuprofen or aspirin. However, warnings advise caution with any co-administered drugs that cause further CNS depression (drowsiness) or those metabolized by specific liver enzymes (CYP enzymes).

---

Q: Are there any known laboratory test interferences associated with Phenaemaletten?

Yes, Phenobarbital may interfere with the results of certain laboratory tests, particularly those for thyroid function. It can also cause an elevation in certain liver enzyme tests which can complicate the interpretation of those results.

---

Q: Is Phenaemaletten widely available in different countries?

The active ingredient, Phenobarbital, is recognized globally as an established core medicine. Its status as an essential medication is confirmed by its inclusion on the World Health Organization Model List of Essential Medicines for seizure management.

Storage Conditions

Official regulatory documents require that Phenaemaletten must be stored at Controlled Room Temperature, typically 20^circ to 25 C. The tablets must be protected from light and moisture to maintain the stability of the active ingredient, Phenobarbital.

Container and Child Safety

To prevent degradation, the medication must be stored in a tight, light-resistant container. Due to its classification as a controlled substance, a fundamental requirement is to keep this medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Phenaemaletten must not be disposed of in household trash or down a drain. All disposal must strictly follow the local, state, and federal regulations applicable to Schedule IV controlled substances.